Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma-Reference-Cited by-同舟云学术

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma

Published:2012 Issue:1 Volume:47 Page:60
ISSN:1738-7949
Container-title:The Korean Journal of Hematology
language:en
Short-container-title:Korean J Hematol

Author:

Kim Jeong Eun¹,Yoon Dok Hyun¹,Kim Shin¹,Lee Dae Ho¹,Kim Jeong Hoon²,Yoon Young Hee³,Chi Hyun Sook⁴,Lee Sang Wook⁵,Park Chan-Sik⁶,Huh Jooryung⁶,Suh Cheolwon¹

Affiliation:

1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

2. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

3. Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

4. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

5. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

6. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/kjh.2012.47.1.60

Reference13 articles.

1. Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support

2. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions

3. Therapeutic challenges in primary CNS lymphoma

4. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience

5. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Center Real-World Experience with Primary Central Nervous System Lymphoma in the 21st Century;The Korean Journal of Medicine;2024-02-01

2. Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study;Frontiers in Oncology;2022-07-11

3. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma;Journal of Neuro-Oncology;2021-12-01

4. Prognostic models in primary central nervous system lymphoma patients: A systematic review;Critical Reviews in Oncology/Hematology;2021-05

5. Relapsed Primary Central Nervous System Lymphoma: Current Advances;Frontiers in Oncology;2021-04-29